Trials / Unknown
UnknownNCT04573998
Study on the Mechanism of lcn2 in Obesity
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Shen Qu · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Obesity is now becoming a worldwide serious problem. Obesity is associated with a spectrum of severe diseases, including diabetes, cardiovascular diseases, and cancers. Lipocalin 2 (LCN2), also known as neutrophil gelatinase associated lipocalin (NGAL), is a member of the lipocalin family. Due to its upregulated expression in infection, LCN2 is originally considered to be a key regulator of immune response. Subsequent investigations revealed that LCN2 is expressed in many tissues and is related to a variety of diseases, including obesity. LCN2 was reported to be increased in obesity individuals. Thus, the investigators decide to investigate the relationship between LCN2 and obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | LSG | bariatric surgery |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2024-03-01
- Completion
- 2024-05-30
- First posted
- 2020-10-05
- Last updated
- 2020-10-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04573998. Inclusion in this directory is not an endorsement.